Cardiovascular and microvascular outcomes with <scp>iGlarLixi</scp> versus <scp>iDegLira</scp>: A real‐world, population‐based cohort study

Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors. Genome-wide association combined with clonal lineage tracing and clinical trials have demonstrated that innate and adaptive immune responses can promote or quell atherosclerosis. Several signaling pathways, that are associated with the inflammatory response, have been implicated within atherosclerosis such as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt signaling pathways, which are of importance for atherosclerosis development and regression. Targeting inflammatory pathways, especially the NLRP3 inflammasome pathway and its regulated inflammatory cytokine interleukin-1β, could represent an attractive new route for the treatment of atherosclerotic diseases. Herein, we summarize the knowledge on cellular participants and key inflammatory signaling pathways in atherosclerosis, and discuss the preclinical studies targeting these key pathways for atherosclerosis, the clinical trials that are going to target some of these processes, and the effects of quelling inflammation and atherosclerosis in the clinic.

show abstract

“…Because the associated glycemic reduction may also decrease the long-term risk of cardiovascular and microvascular disease. 327 …”

Section: Atherosclerosis Therapiesmentioning

confidence: 99%

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Kong

Cui

Huang

et al. 2022

Sig Transduct Target Ther

436

173

View full text Add to dashboard Cite

show abstract

“… 13 Data on the CV safety of GLP-1RA plus basal insulin FRC as a class are lacking, while a retrospective study directly comparing iGlarLixi and iDegLira showed a lower risk of myocardial infarction, stroke and heart failure in patients using iGlarLixi. 45 …”

Section: Discussionmentioning

confidence: 99%

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis

Caruso,

Di Gioia,

Di Molfetta

et al. 2023

eClinicalMedicine

View full text Add to dashboard Cite

Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real‐world, population‐based cohort study

Cited by 2 publications

References 23 publications

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis

Contact Info

Product

Resources

About